浙江奥翔药业股份有限公司 2025 年第一次临时股东大会 会议资料 股票简称：奥翔药业 股票代码：603229 中国·浙江·临海 2025 年 11 月 18 日 浙江奥翔药业股份有限公司 （一）主持人宣布会议开始； （二）主持人介绍本次会议出席情况； （三）宣读奥翔药业2025年第一次临时股东大会会议须知； （四）宣读股东大会审议议案： 1、《关于取消监事会并修订〈公司章程〉的议案》； 2、《关于修订公司部分内部管理制度的议案》。 2025 年第一次临时股东大会议程 一、会议时间 现场会议时间：2025年11月18日14点00分； 网络投票时间：采用上海证券交易所网络投票系统，通过交易系统投票平台 的投票时间为股东大会召开当日的交易时间段，即9:15-9:25,9:30-11:30， 13:00-15:00 ；通 过互 联网 投票平 台的 投票 时间为 股东 大会 召开 当日的 9:15-15:00。 二、现场会议地点 浙江省化学原料药基地临海园区东海第四大道5号公司新办公楼一楼会议室 三、会议主持人 公司董事长：郑志国先生 四、会议议程 五、股东审议议案； 六、推选计票人和监票人； 七、主持人宣读出席现场 ...

证券日报网讯 11月3日晚间，奥翔药业发布公告称，2025年10月，公司未实施股份回购。 （文章来源：证券日报） ...

格隆汇11月3日丨奥翔药业(603229.SH)公布，截至2025年10月31日，公司通过集中竞价交易方式已累计 回购股份520.12万股，已回购股份占公司总股本的比例为0.63%，成交的最高价为11.39元/股、最低价为 7.52元/股，已支付的总金额为5000.60万元（不含交易费用）。 ...

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 5.2012 million shares, which represents 0.63% of the company's total share capital [1] - The highest price paid for the repurchased shares was 11.39 yuan per share, while the lowest price was 7.52 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, is 50.006 million yuan [1]

证券代码：603229 证券简称：奥翔药业 公告编号：2025-049 浙江奥翔药业股份有限公司 一、回购股份的基本情况 浙江奥翔药业股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日召开 第四届董事会第六次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司使用自有资金和/或自筹资金以集中竞价交易方式回购公 司已发行的部分人民币普通股（A 股）股票，本次回购的股份拟在未来用于实施股 权激励和/或员工持股计划。本次回购的资金总额不低于人民币 5,000 万元（含）， 不超过人民币 10,000 万元（含），回购价格不超过人民币 14 元/股（含），回购期 限为自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公 司分别于 2025 年 1 月 27 日、2025 年 2 月 6 日披露的《奥翔药业关于以集中竞价 交易方式回购公司股份方案的公告》（公告编号：2025-002）、《奥翔药业关于以集 中竞价交易方式回购股份的回购报告书》（公告编号：2025-005）。 因公司实施 2024 年年度权益分派，自 2025 年 7 月 17 日起，本次回购股份 ...

Core Viewpoint - The company reported a decline in revenue for Q3 2025, with a slight increase in gross margin, while net profit and net profit margin decreased year-on-year and quarter-on-quarter [2] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 646 million yuan, a year-on-year decrease of 6.40%, and a net profit of 207 million yuan, down 9.59% year-on-year [1] - In Q3 2025, the company generated revenue of 164 million yuan, a year-on-year decline of 17.01%, with a net profit of 38 million yuan, down 23.33% year-on-year [2] - The gross margin for Q3 was 53.32%, showing a year-on-year increase of 0.03 percentage points, while the net profit margin was 22.97%, down 1.89 percentage points year-on-year [2] Research and Development - The company has significantly increased its R&D investment, with R&D expenses reaching 81.62 million yuan in the first three quarters of 2025, a year-on-year increase of 27.49%, marking a historical high for the period [3] - The R&D expense ratio for the first three quarters was 12.64%, indicating a commitment to enhancing R&D capabilities and expanding the team to nearly 500 members [3] - The company is focusing on synthetic biology and peptide drugs, with plans to develop innovative drugs, including a new drug for ischemic stroke that is pending entry into phase III clinical trials [3] Future Outlook - The company is expected to see revenue growth in the coming years, with projected revenues of 832 million yuan, 978 million yuan, and 1.213 billion yuan for 2025, 2026, and 2027, respectively [4] - The net profit forecasts for the same years are 241 million yuan, 394 million yuan, and 382 million yuan, with corresponding price-to-earnings ratios of 34, 28, and 22 times [4] - The company anticipates that its collaboration with STADA on a new formulation product will begin contributing to sales in the second half of 2025 [3]

Core Insights - Aoshang Pharmaceutical (603229.SH) reported its Q3 2025 results on October 31, 2025, indicating a total of 53.1 million shares held by six institutional investors, representing 6.40% of the company's total equity [1] Institutional Holdings - The total institutional holding decreased by 1.54 percentage points compared to the previous quarter [1] - The institutional investors include Jiaxing Aoshang Equity Investment Management Partnership, Shanghai Duxi Bingtai Private Fund Management Co., Ltd., Taizhou Jinkong Asset Management Co., Ltd., and others [1] Public Fund and Foreign Investment - There were 68 public funds that did not disclose holdings in this period, including several ETFs focused on the CSI 1000 index [1] - Foreign investment saw a slight increase with one foreign fund, Hong Kong Central Clearing Limited, increasing its holdings [1]

Core Points - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has revised its internal management systems and company charter to enhance governance and compliance with relevant laws and regulations [1][12][16] - The company plans to hold a Q3 2025 performance briefing on November 11, 2025, to discuss its financial results and address investor inquiries [5][6][7] - The company has announced a temporary shareholders' meeting scheduled for November 18, 2025, to discuss various proposals, including the cancellation of the supervisory board and amendments to the company charter [32][33][34] Group 1: Company Governance and Internal Management - The company has revised its charter and internal management systems to improve governance and ensure compliance with the Company Law and Securities Law of the People's Republic of China [1][12] - The revised internal management systems were approved by the board and will take effect after shareholder approval [1][12] Group 2: Q3 Performance Briefing - The Q3 2025 performance briefing will take place on November 11, 2025, from 15:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [5][6] - Investors can submit questions from November 4 to November 10, 2025, and the company will address common concerns during the briefing [5][6][7] Group 3: Shareholders' Meeting - The first temporary shareholders' meeting of 2025 is set for November 18, 2025, with both on-site and online voting options available [32][33][34] - The meeting will discuss the cancellation of the supervisory board and the revision of the company charter, among other matters [32][33][34]

Core Viewpoint - Aoxiang Pharmaceutical is a significant player in the domestic specialty API and pharmaceutical intermediates sector, showcasing strong R&D capabilities and a complete industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Aoxiang Pharmaceutical reported revenue of 646 million yuan, ranking 25th among 47 companies in the industry, with the industry leader, Puluo Pharmaceutical, generating 7.764 billion yuan [2] - The company's net profit for the same period was 207 million yuan, placing it 12th in the industry, while the top performer, Zhejiang Pharmaceutical, achieved 867 million yuan [2] Group 2: Financial Ratios - Aoxiang Pharmaceutical's debt-to-asset ratio stood at 23.30% in Q3 2025, lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin was 56.93%, above the industry average of 35.38%, reflecting robust profitability despite a slight decrease from the previous year's margin of 57.94% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 5.64% to 32,000, while the average number of circulating A-shares held per shareholder decreased by 5.34% to 25,900 [5] - The ninth largest circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 160,600 shares [5] Group 4: Future Outlook - Analysts from Zhongtai Securities noted that while the company faced short-term profit pressure due to product structure changes and increased competition, the growth potential in its formulation and CDMO businesses remains promising [5] - Pacific Securities highlighted that Aoxiang Pharmaceutical's R&D expenses reached a record high in H1 2025, indicating a commitment to innovation, with expectations for revenue growth in the coming years [6]

Core Insights - The company reported a revenue of 646 million yuan for the first three quarters of 2025, representing a year-on-year decline of 6.40% [1] - The net profit attributable to the parent company was 207 million yuan, down 9.59% year-on-year [1] - The non-recurring net profit was 183 million yuan, reflecting a year-on-year decrease of 13.83% [1] - The basic earnings per share stood at 0.25 yuan [1]